Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2023
Same author

Childhood Disadvantage Moderates Late Midlife Default Mode Network Cortical Microstructure and Visual Memory Association.

The journals of gerontology. Series A, Biological sciences and medical sciences·2023
Same author

Heritability Estimation of Cognitive Phenotypes in the ABCD Study<sup>®</sup> Using Mixed Models.

Behavior genetics·2023
Same author

Task fMRI paradigms may capture more behaviorally relevant information than resting-state functional connectivity.

NeuroImage·2023
Same author

Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders.

Brain : a journal of neurology·2023
Same author

A Multicompartmental Diffusion Model for Improved Assessment of Whole-Body Diffusion-weighted Imaging Data and Evaluation of Prostate Cancer Bone Metastases.

Radiology. Imaging cancer·2023
Same journal

Thymidylate synthase inhibitory drugs induce p53-dependent pathways differently.

PloS one·2026
Same journal

Top-down and bottom-up attention for joint pattern classification and reconstruction.

PloS one·2026
Same journal

Short- and long-term scaling behavior of blood pressure and pulse arrival time during sleep in healthy controls and patients with obstructive sleep apnea.

PloS one·2026
Same journal

Double DQN-based secrecy energy efficiency and fairness performance in IRS-assisted NOMA systems with friendly jamming.

PloS one·2026
Same journal

10 recommendations for strengthening citizen science for improved societal and ecological outcomes: A co-produced analysis of challenges and opportunities in the 21st century.

PloS one·2026
Same journal

Paying in public: Peer effects, impression management, and willingness to pay on digital payment platforms.

PloS one·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Rates of decline in Alzheimer disease decrease with age.

Dominic Holland1, Rahul S Desikan, Anders M Dale

  • 1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America. dominic.holland@gmail.com

Plos One
|August 10, 2012
PubMed
Summary
This summary is machine-generated.

Older individuals over 85 show milder Alzheimer's disease (AD) progression and brain atrophy. This finding impacts clinical trial power and sample size calculations for AD therapeutics.

More Related Videos

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Related Experiment Videos

Last Updated: May 19, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Area of Science:

  • Neuroscience
  • Gerontology
  • Medical Research

Background:

  • Age is the primary risk factor for sporadic Alzheimer's disease (AD).
  • The influence of aging on AD clinical decline and brain atrophy rates remains under-explored.

Purpose of the Study:

  • To investigate how baseline age affects longitudinal rates of clinical decline and brain atrophy in Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy controls (HC).

Main Methods:

  • Utilized mixed-effects linear regression to model age-related changes in clinical and structural MRI measures.
  • Analyzed data from 723 individuals (AD, MCI, HC) aged 65-90 years.
  • Examined cerebrospinal fluid (CSF) protein levels (Aβ(1-42), tau, ptau) and baseline clinical severity.

Main Results:

  • AD and MCI patients exhibited reduced rates of decline and atrophy with increasing age.
  • Healthy controls showed increased rates of decline and atrophy with age, leading to convergence with patient groups.
  • Cerebrospinal fluid (CSF) protein levels, especially ptau, converged across groups in older individuals.
  • Baseline clinical severity was uniform across all age groups.

Conclusions:

  • The phenotypic expression of AD appears milder in individuals over 85, potentially complicating AD diagnosis in the very old.
  • Including older participants in clinical trials may significantly reduce statistical power and necessitate larger sample sizes for detecting therapeutic effects.